Production value of pharmaceutical drugs Japan 2013-2022

The total production value of medical drugs in Japan amounted to approximately ten trillion Japanese yen in 2022. The figure increased compared to around 9.17 trillion yen in the previous year. Prescription drugs represent the staple products of the medical drug market, accounting for almost 92 percent of the annual production value. Domestic pharmaceutical industrySurpassed by only the United States and China, the pharmaceutical market in Japan is one of the largest worldwide. Major domestic key players include multinational businesses competing on a global scale. Following the acquisition of Shire, the Tokyo-based Takeda Pharmaceutical Co., Ltd. was forecasted to join the ranks as a leading pharmaceutical company worldwide. While the industry is subjected to extensive regulatory stipulations and long approval processes, the Japanese government has been working on a simplified framework to accelerate research and development efforts in the country. The transformation of the market offers domestic and foreign competitors a variety of opportunities, with the challenges of an aging society becoming a key driver for future growth. Demographic challenges turning to opportunitiesThe high life expectancy of the population raises new challenges for the healthcare system, coupled with an increasing demand for medical treatment. In particular generics, commonly used in the treatment of elderly patients, are growing in importance. In 2022, antineoplastic agents accounted for one of the largest shares of medical drug production in Japan.

2022年，日本医药产品的总产值约为十万亿日元。相较于前一年的约9.17万亿日元，这一数字有所上升。处方药作为医药市场的主导产品，占据了年度生产价值的近92%。仅在美国和中国之后，日本的医药市场是全球最大的医药市场之一。国内主要的关键参与者包括在全球范围内竞争的跨国企业。在收购Shire之后，总部位于东京的武田药品工业株式会社预计将跻身全球领先制药公司的行列。尽管该行业受到广泛的监管规范和漫长的审批流程的制约，但日本政府一直在致力于构建简化的框架，以加速国内的研究与开发工作。市场的变革为国内外竞争者提供了多样化的机遇，而老龄化社会的挑战正成为未来增长的关键驱动力。人口结构挑战转化为机遇随着人口的预期寿命延长，医疗保健系统面临新的挑战，同时对于医疗治疗的需求也在不断增长。特别是，在老年患者治疗中广泛使用的通用药物，其重要性正在日益凸显。2022年，抗肿瘤药物占日本医药产品生产份额的较大比例。